AU1481795A - Antibody conjugates with improved properties - Google Patents

Antibody conjugates with improved properties

Info

Publication number
AU1481795A
AU1481795A AU14817/95A AU1481795A AU1481795A AU 1481795 A AU1481795 A AU 1481795A AU 14817/95 A AU14817/95 A AU 14817/95A AU 1481795 A AU1481795 A AU 1481795A AU 1481795 A AU1481795 A AU 1481795A
Authority
AU
Australia
Prior art keywords
improved properties
antibody conjugates
conjugates
antibody
properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14817/95A
Other languages
English (en)
Inventor
Not Given Name
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU1481795A publication Critical patent/AU1481795A/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Amend patent request/document other than specification (104) Assignors: CIBA-GEIGY AG
Priority to AU37986/99A priority Critical patent/AU3798699A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU14817/95A 1994-03-21 1995-03-14 Antibody conjugates with improved properties Abandoned AU1481795A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37986/99A AU3798699A (en) 1994-03-21 1999-07-05 Antibody conjugates with improved properties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810173 1994-03-21
EP94810173 1994-03-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU37986/99A Division AU3798699A (en) 1994-03-21 1999-07-05 Antibody conjugates with improved properties

Publications (1)

Publication Number Publication Date
AU1481795A true AU1481795A (en) 1995-09-28

Family

ID=8218230

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14817/95A Abandoned AU1481795A (en) 1994-03-21 1995-03-14 Antibody conjugates with improved properties

Country Status (11)

Country Link
JP (1) JPH0820545A (hu)
KR (1) KR950031111A (hu)
AU (1) AU1481795A (hu)
CA (1) CA2144936A1 (hu)
FI (1) FI951276A (hu)
HU (1) HUT71776A (hu)
IL (1) IL113022A (hu)
NO (1) NO951061L (hu)
NZ (1) NZ270734A (hu)
RU (1) RU95104325A (hu)
ZA (1) ZA952269B (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865737B1 (fr) * 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible

Also Published As

Publication number Publication date
RU95104325A (ru) 1996-12-27
KR950031111A (ko) 1995-12-18
FI951276A (fi) 1995-09-22
IL113022A0 (en) 1995-06-29
IL113022A (en) 2000-02-29
CA2144936A1 (en) 1995-09-22
NO951061D0 (no) 1995-03-20
FI951276A0 (fi) 1995-03-17
HU9500586D0 (en) 1995-04-28
ZA952269B (en) 1995-09-21
JPH0820545A (ja) 1996-01-23
HUT71776A (en) 1996-01-29
NO951061L (no) 1995-09-22
NZ270734A (en) 1997-05-26

Similar Documents

Publication Publication Date Title
AU3811495A (en) Antibodies
AU7101094A (en) Factor ix - polymeric conjugates
AU6029594A (en) Factor viii - polymeric conjugates
AU2372397A (en) Interferon conjugates
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
AU2958997A (en) Concentrated antibody preparation
AU6711994A (en) Rapamycin conjugates and antibodies
AUPN178995A0 (en) Antigen composition
AU4344696A (en) Oligonucleotide-dendrimer conjugates
AU2540295A (en) Folder with built-in lamp
AU2878989A (en) Antibody conjugates
AU1481795A (en) Antibody conjugates with improved properties
AU5009993A (en) Isoprostane-protein conjugates
AU6044094A (en) Napkin with buffer substance
AU1809695A (en) Tumor associated monoclonal antibody 123av16
AU2887195A (en) Kit for pretargeting and novel pretargeting conjugates
AU7862291A (en) Modified antibodies
AUPM419494A0 (en) Improved full-open end
AU1410995A (en) Cross-reactive allergen
GB9419256D0 (en) Antibody and conjugates
AUPM430294A0 (en) Polymer antibody attachment
AUPM447694A0 (en) Antigen composition
AU1241499A (en) Transformer with improved integrated potentiometer
AU701885C (en) Monoclonal antibody active against CD44v6
ZA9510827B (en) Oligonucleotide-dendrimer conjugates